Edgewise Therapeutics Inc
NASDAQ:EWTX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.42
30.03
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Edgewise Therapeutics Inc
NASDAQ:EWTX
|
3.1B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.6B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Edgewise Therapeutics Inc
Glance View
Edgewise Therapeutics Inc. is a biopharmaceutical company that has carved its niche by focusing intently on developing treatments for rare muscle disorders. Founded with the vision of addressing the unmet needs within the realm of muscular dystrophies and other rare myopathies, Edgewise aims to combat these challenges through precision medicine. Its unique approach lies in leveraging its proprietary drug discovery platform to identify and develop small molecule therapies that target the underlying causes of these muscle disorders. By honing in on the mechanistic roots of muscle dysfunction, Edgewise aspires to improve the quality of life for patients who often have limited treatment options available. The company generates revenue primarily through the successful development and potential commercialization of its therapies. As with many biopharmaceutical entities, the cornerstone of Edgewise's financial strategy is to push its drug candidates through the clinical trial phases efficiently, demonstrating safety and efficacy to obtain regulatory approval. Partnerships, collaborations, and licensing agreements often play a critical role in supplementing its revenue stream, enabling Edgewise to leverage additional resources and expertise. By addressing the therapeutic gaps in rare muscle disorders with promising candidates that have the potential to be first-in-class or best-in-class treatments, Edgewise Therapeutics strategically positions itself to create significant value for its patients and stakeholders alike.